In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.

Maddalo et al. Nature (2014) 516:423-427. http://www.ncbi.nlm.nih.gov/pubmed/25337876

Many human cancers are the result of chromosomal rearrangements which has made modeling certain cancers in mice challenging.  Using CRISPR/Cas9 gene editing Maddalo et al. were able to induce chromosomal rearrangements similar to those found non-small cell lung cancers in mouse lung tissue.  CRISPR/Cas9 modified mice developed lung tumors when compared to control mice demonstrating the capability of CRISPR/Cas9 technology to selectively edit mouse tissues to study human cancers.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply